Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Radical -xh acid – or anhydride – acid halide or salt thereof...
Reexamination Certificate
2010-09-23
2011-12-06
Vu, Jake M. (Department: 1618)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Radical -xh acid, or anhydride, acid halide or salt thereof...
C424S486000
Reexamination Certificate
active
08071648
ABSTRACT:
Topical suspension compositions of nepafenac are disclosed. The compositions are especially suitable for topical ophthalmic administration.
REFERENCES:
patent: 3828093 (1974-08-01), Bays et al.
patent: 4045576 (1977-08-01), Welstead, Jr. et al.
patent: 4126635 (1978-11-01), Welstead, Jr. et al.
patent: 4182774 (1980-01-01), Welstead, Jr. et al.
patent: 4254146 (1981-03-01), Walsh
patent: 4313949 (1982-02-01), Shanklin, Jr. et al.
patent: 4503073 (1985-03-01), Walsh et al.
patent: 4568695 (1986-02-01), Moran et al.
patent: 4683242 (1987-07-01), Poser
patent: 4783487 (1988-11-01), Brune
patent: 4851443 (1989-07-01), Brune
patent: 4910225 (1990-03-01), Ogawa et al.
patent: 5073641 (1991-12-01), Bundgaard et al.
patent: 5461081 (1995-10-01), Ali et al.
patent: 5475034 (1995-12-01), Yanni et al.
patent: 5521222 (1996-05-01), Ali et al.
patent: 5624893 (1997-04-01), Yanni
patent: 6342524 (2002-01-01), Hellberg et al.
patent: 6638976 (2003-10-01), Gamache et al.
patent: 2002/0037929 (2002-03-01), Kapin et al.
patent: 2003/0207941 (2003-11-01), Bingaman et al.
patent: 2005/0239895 (2005-10-01), Sawa et al.
patent: 2071086 (1981-09-01), None
patent: 2093027 (1982-08-01), None
patent: WO0213805 (2002-02-01), None
patent: WO03092669 (2003-11-01), None
L. F. Sancilio, et al., “AHR-10037, a Non-Steroidal Anti-Inflammatory Compound of Low Gastric Toxicity,” Agents and Actions, 1990, pp. 177-126, vol. 31.
Tai-Lee Ke, et al., “Nepafenac, a Unique Nonsteroidal Prodrug with Potential Utility in the Treatment of Trauma-Induced Ocular Inflammation: II. In Vitro Bioactiviation and Permeation of External Ocular Barriers,” Inflammation, 2000, pp. 371-384, vol. 24(4).
David A. Walsh, et al., “Antiinflammatory Agents. 3. Syntheses and Pharmacological Evaluation of 2-Amino-3-Benzoylphenylacetic Acid and Analogues,” J, Med. Chem., 1984, pp. 1379-1388, vol. 27(11).
David A. Walsh, et al., “Antiinflammatory Agents. 4. Synthesis and Biological Evaluation of Potential Prodrugs of 2-Amino-3-Benzoylbenzeneacetic Acid and 2-Amino-3-(4-Chlorobenzoyl)Benzeneacetic Acid,” J. Med. Chem., 1990, pp. 2296-2304, vol. 33.
J. S. Penn, et al., “Studies of the Effect and Mechanism of Action of Topical Nepafenac in a Rat Model of ROP,” ARVO Annual Meeting, Fort Lauderdale, Florida, May 5-10, 2002, Abstract 2741.
Novartis AG
Ryan Patrick M.
Vu Jake M.
LandOfFree
Topical nepafenac formulations does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Topical nepafenac formulations, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Topical nepafenac formulations will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4263998